Emergence of deadly fentanyl-xylazine combo ‘tranq’ worsens the addiction epidemic

Amid a catastrophic addiction epidemic, a new drug cocktail known as “tranq” has emerged as a serious threat across the U.S.

According to the U.S. Department of Justice Drug Enforcement Administration, tranq — a mixture of the synthetic opioid fentanyl and the animal tranquilizer xylazine — has been found in 48 states. The DEA recently issued a dire warning about the potential for overdoses and severe skin ulcers that may lead to amputations.

Tranq does not respond to naloxone, the opioid-reversal drug that has averted many deaths from fentanyl. Consequently, more people who use tranq are dying. Adam Leventhal, director of the USC Institute for Addiction Science, says that the drug is an urgent threat that requires a strong response.

“People with fentanyl-use disorders might not want xylazine in their product, but suppliers are adding it to the fentanyl supply,” Leventhal said. “This drug, combined with the effects of fentanyl, creates a different type of psychoactive effect that’s a new experience for the user. Risk of overdose increases when these two powerful drugs are combined.

Addiction will always be a constantly evolving proble.

Adam Leventhal, USC Institute for Addiction Science

“Addiction will always be a constantly evolving problem. We need policy experts, public health researchers, economists and legal analysts who study the drug industry to inform policies that regulate the supply side. And we need social workers, psychologists and neuroscientists to understand the demand side: Why is a certain drug addicting? What treatments will reduce that demand?”

Tranq: Trend began on the East Coast

The tranq trend began on the East Coast and quickly moved west, according to Daryl Davies, an expert on the pharmacology and toxicology of drugs of abuse in the Titus Family Department of Clinical Pharmacy at the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. He warns that people who feel safer using fentanyl because of naloxone may be unaware of new dangers posed by the cocktail drug.

The Street Medicine Team at the Keck School of Medicine of USC is working on procuring test strips so patients can identify when their drug is contaminated with xylazine. Jungeun Olivia Lee, an associate professor at the USC Suzanne Dworak-Peck School of Social Work, wants to see nonstigmatizing, developmentally appropriate messages for teens, to warn them away.

“The initiation of substance use reaches its peak during adolescence,” Lee said. “The consequences of substance use — particularly potent drugs like fentanyl combined with xylazine — can be a lot more substantial for teenagers compared to adults, given that their social, psychological and physiological functioning is still developing. …

“Prevention and intervention strategies developed for adults may not be necessarily effective for teenagers.”

Fentanyl abuse still rocking U.S., but safe sites remain unpopular

Illicit fentanyl on its own has rocked California’s cities and the nation. One proposed policy solution is the creation of drug-use site pilot programs — also known as safe injection sites — in Oakland, Los Angeles and San Francisco where drug addicts can safely use illegal drugs while under supervision to prevent overdoses.

But the USC Schwarzenegger Institute for State and Global Policy’s latest California Issues poll shows that a majority of Californians — 54% overall — disapprove of the sites (42% strongly disapproved and 12% slightly disapproved). Meanwhile, 36% overall supported them, with 17% saying they strongly approved and 19% saying they slightly approved.

“Gov. Newsom in 2022 vetoed a bill that would have created these drug-use pilot sites,” said Christian Grose, the academic director of the USC Schwarzenegger Institute and a political science and public policy professor at the USC Dornsife College of Letters, Arts and Sciences. “While the fentanyl crisis is important, the issue of pilot drug-use sites has been politically unpalatable to Newsom. If Newsom hopes to run for president, this is an unpopular reform across the United States. And even here in California, voters are very split on the issue.”

Despite an aversion to safe-use sites, governments are increasingly active in curbing the addiction epidemic, Leventhal says. “It’s unprecedented what they’re doing recently for addiction and overdose prevention and harm reduction.

“We are aligned with the belief that keeping people who use substances alive is a human right. Everyone deserves an opportunity to get on a path to recovery.”

The post Emergence of deadly fentanyl-xylazine combo ‘tranq’ worsens the addiction epidemic appeared first on USC News.

USC scientists see a key role for AI and 3D modeling in drug discovery

Artificial intelligence can generate poems and essays, create responsive game characters, analyze vast amounts of data and detect patterns that the human eye might miss. Imagine what AI could do for drug discovery, traditionally a time-consuming, expensive process from the bench to the bedside.

Experts see great promise in a complementary approach using AI and structure-based drug discovery, a computational method that relies on knowledge of 3D structures of biological targets.

We recently caught up with Vsevolod “Seva” Katritch, associate professor of quantitative and computational biology and chemistry at the USC Dornsife College of Letters, Arts and Sciences and the USC Michelson Center for Convergent Bioscience. Katritch is the co-director of the Center for New Technologies in Drug Discovery and Development (CNT3D) at the USC Michelson Center and the lead author of a new review paper in Nature. The paper, co-authored by USC research scientist Anastasiia Sadybekov, describes how computational approaches will streamline drug discovery.

We’re on the cusp of major advances in drug discovery. What brings us to this moment?

There has been a seismic shift in computational drug discovery in the last few years: an explosion of data availability on clinically relevant, human-protein structures — and molecules that bind them, enormous chemical libraries of drug-like molecules, almost unlimited computing power and new, more efficient computational methods. The newest excitement is about AI-based drug discovery, but what’s even more powerful is a combination of AI and structure-based drug discovery, with both approaches synergistically complementing each other.

How has drug discovery been done in the past?

Traditional drug discovery is mostly a trial-and-error venture. It’s slow and expensive, taking an average of 15 years and $2 billion. There’s a high attrition rate at every step, from target selection to lead optimization. The most opportunities for time and cost savings reside in the earlier discovery and preclinical stages.

What takes place in the early stage?

Let’s use a lock-and-key analogy. The target receptor is the lock, and the drug that blocks or activates this receptor is a key for this lock. (Of course, the caveat is that in biology nothing is black or white, so some of the working keys switch the lock better than others, and lock is a bit malleable too.)

Here’s an example. Lipitor, the bestselling drug of all time, targets an enzyme involved in the synthesis of cholesterol in the liver. A receptor on the enzyme is the lock. Lipitor is the key, fitting into the lock and blocking the activity of the enzyme, triggering a series of events that decrease blood levels of bad cholesterol.

Now, computational approaches allow us to digitally model many billions and even trillions of virtual keys and predict which ones are likely to be good keys. Only a few dozen of the best candidate keys are chemically synthesized and tested.

This sounds much more efficient.

If the model is good, this process yields better results than traditional trial-and-error testing of millions of random keys. This reduces the physical requirements for synthesis of compounds and testing them more than thousandsfold, while often arriving at better results, as demonstrated by our work and work of many other groups working in this field.

Can you explain the difference between the two main computational approaches, structure-based and AI-based?

Following the lock-and-key analogy, the structure-based approach takes advantage of our detailed understanding of the lock’s structure. If the 3D, physical structure of the lock is known, we can use virtual methods to predict the structure of a key that matches the lock.

The machine learning, or AI-based approach, works best when many keys are already known for our target lock or other similar locks. AI can then analyze this mixture of similar locks and keys and predict the keys that are most likely to fit our target. It does not need exact knowledge of the lock structure, but it needs a large collection of relevant keys.

Thus, the structure-based and AI-based approaches are applicable in different cases and complement each other.

Are there any computational limits to this process?

When testing billions and trillions of virtual compounds on cloud computers, computational costs themselves can become a bottleneck. A modular, giga-scale screening technology allows us to speed up and reduce cost dramatically by virtually predicting good parts of the key, combine them together, sort of building the key from several parts. For a 10 billion-compound library, this drops the computational costs from millions of dollars to hundreds, and it allows further scale-ups to trillions of compounds.

How will these approaches help discovery of new disease treatments at USC?

Our Center for New Technologies in Drug Discovery and Development (CNT3D) recently co-created at USC Dornsife with chemistry Professor Charles McKenna is largely based on this computationally driven concept. The center implements a number of structure-based and AI-based methods as a platform. CNT3D collaborates with labs at Keck Medicine of USC, MESH Academy, the Rosalie and Harold Rae Brown Center for Cancer Drug Development and the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences on specific disease targets like Alzheimer’s and cancer, already discovering potential drug candidates for these and other diseases. We plan to dramatically scale up this work in the next few months and involve more labs in these studies via Drug Discovery Innovation workshops, building a unique technology-driven type of drug discovery ecosystem at USC.

The post USC scientists see a key role for AI and 3D modeling in drug discovery appeared first on USC News.

Why are COVID-19 vaccination rates among children so low?

8321 school/unit website *
https://dornsife.usc.edu/news/stories/3835/why-low-covid-19-vaccination-among-children/
Story Headline and Deck – USC News *
Why are COVID-19 vaccination rates among children so low? Parents’ worry about long-term risks, responsibility

Parents worry about potential long-term risks from the vaccine, and some fear they’ll be viewed as responsible if their child becomes sick after the vaccination, USC research finds.

Body Copy *
Despite efforts by the U.S. Centers for Disease Control and Prevention and pediatric clinicians to increase the COVID-19 vaccination rate among children, many remain unvaccinated due to parental concerns about the vaccine’s long-term effects and anticipated responsibility. Those are findings from a new study published in Pediatrics and conducted by the Center for Economic and Social Research(CESR) at the USC Dornsife College of Letters, Arts and Sciences.

The researchers sought to determine the causes of low child vaccination rates. Currently, only 39% of children 5 to 11 and 68% of those 12 to 17 have received vaccinations, compared to 92% of adults.

During the Omicron variant’s spike between February and March 2022, when pediatric COVID-19 cases peaked, the USC Dornsife survey of parents in the nationally representative Understanding America Study revealed that 45% of parents believed the vaccine’s long-term risks to their child outweighed the risks of not being vaccinated.

Ying Liu, research scientist at CESR and the study lead, explained that “parents’ hesitancy may be partly driven by apprehension about the vaccine, stemming from its rapid development and the use of newer techniques.”

Additionally, 18% of parents said they’d feel a heightened sense of responsibility if their child became sick following vaccination.

“People often exhibit a more cautious approach when making medical decisions for others, including their own children, than for themselves,” Liu said. “Some tend to do nothing rather than vaccinate their child, even though such inaction could result in negative consequences.”

Said Arie Kapteyn, director of CESR and professor (research) of economics at USC Dornsife: “This research underscores the pressing need to address parental perceptions of the COVID-19 vaccine. By doing so, we believe the vaccination rate among 5- to 17-year-olds could be increased to over 50%.”

The report suggests the following ways to boost child vaccination rates:

Assure parents that side effects from the vaccine are rare and mild, whereas the health complications from the COVID-19 infection are far more common and severe.

Highlight that there is no evidence or plausible way in which the vaccine could alter a child’s genetic makeup.

Emphasize the potential and avoidable negative outcomes from lack of action when delaying or foregoing the vaccination.

The post Why are COVID-19 vaccination rates among children so low? appeared first on USC News.

How surfing could help alleviate chronic pain

8289

Scientists Probe How Surfing Could Help Chronic Pain

Story Headline and Deck – USC News *
Scientists Probe How Surfing Could Help Chronic Pain

USC researchers are scanning patients’ brains after they catch waves — and constructing a virtual reality surfing experience.
Body Copy *
Associate Professor Jason Kutch developed chronic pain in his 20s, a condition that eventually became “debilitating and impactful.”

When he moved to Los Angeles in 2008 as a postdoctoral researcher in biomedical engineering, he took up surfing and made a huge, personal discovery: after spending time in the ocean surfing, his pain would subside.

“I started to notice that not only would I be out of pain immediately afterwards — which might have something to do with distraction — but it also seemed to make it less likely that I’d have pain on other days even when I wasn’t surfing,” Kutch says. “It seemed to have this restorative effect.”

After seeing a movie about veterans with post-traumatic stress disorder getting relief from surfing, Kutch had an idea: What if he could study this in a rigorous way?

“I had a dream of taking an MRI machine on a truck up to the surf break and scanning people’s brains before and after surfing,” he says.

Thanks to a Southern California Clinical and Translational Science Institute Multidisciplinary Pilot Grant, Kutch and colleagues Associate Professor James Finley and Gabilan Assistant Professor of Computer Science Heather Culbertson will be able to study how surfing impacts chronic pain sufferers — both in the water and on a complex virtual reality wave.

 

Surfer’s High

One in five Americans suffer from chronic pain, and the researchers’ hope is to understand if ocean surfing therapy could help a group of patients who have had few options for relief.

“There is mounting evidence that many patients with chronic pain have problems with neural signaling that may make it difficult to think about anything other than pain,” Kutch says. “The idea is that the really dynamic environment of surfing might force the brain to focus outside the body and restore a better signaling balance.”

The research team will study two things: how surfing affects the brain, and how to engineer a virtual reality simulation detailed enough to replicate surfing’s benefits to expand access.

To answer those questions, the new study will be multifaceted. First, the team will use an EEG-powered headband to image the brains of study participants each week, before and after a session of surf therapy. They will also scan the brains of experienced surfers to see what happens after a surfing session.

Additionally, they will develop a virtual reality setup, using a motion platform that mimics the sensation of a surfboard. In the first phase, Kutch says they’ll create an immersive environment where the person is sitting on the board wearing a headset while it rocks — basically waiting for a wave in the lineup.

They’ll use both pain patients and skilled surfers to evaluate it. The second phase will bring a dynamic riding of the wave, as the patients stand up and surf in virtual reality.

They hope to find out what part of surfing brings pain relief — is it the dynamic environment of the ocean, or the full-body experience of water, or the act of catching a wave?

From Kutch’s experience, being in the environment is important, but there’s something about the challenge of getting that first wave and successfully riding it.

“I love the idea of trying to figure out how to have people in the water as well and have a more dynamic environment, he says. “And I’m not sure how to do that yet. This piece of equipment is not going to get wet.”

 

A Fully Immersive Experience

The study is also unique in its multidisciplinary partners. Finley has been working for a decade on developing virtual reality-based applications for neuromotor rehabilitation — mostly on ways to recreate mobility-related challenges that people face in the real world.

“One of the nice things about virtual reality is that we can fully control what people see. We can also add a layer of audio and even haptics — where people have some sensory feedback based on their interaction with objects in the virtual environment.”

The system will start with a full motion simulator that you might typically see at a theme park, with a surfboard attached, says Culbertson, who is a faculty member of the USC Viterbi School of Engineering. She is going to program the motion system hardware so that researchers can realistically create the sensation of waves and match it to visual graphics in virtual reality — something that may also include ocean smell and breezes. “We’re not trying to gamify the experience,” she says. “It’s meant to be a fully immersive kind of calming experience that allows users to get that surfer’s high.”

To build the system, the team will gather recordings of surfers to measure their motions using waterproof sensors. They’ll use those to program the device. Recording video is easy, she says — but recording haptics is challenging.

“If we want this to feel realistic, then we need to have those haptic sensations to understand what the user is actually feeling when surfing on real waves,” she says.

Overall, the team hopes to gain a better understanding of how surfing could help chronic pain patients — and figuring out how to make the activity available to a wider swath of people.

Kutch says if the pilot is successful, it could grow into something larger: “I’m really hopeful that we could boil a component of the VR down to a bare minimum that’s needed, and then actually be able to get that out to a lot of people as something they can use in their home or at their local pool in a more practical way.”

The post How surfing could help alleviate chronic pain appeared first on USC News.

USC Schaeffer Center experts offer solutions to ensure greater patient access to prescription drugs

8286

New Schaeffer White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs

Story Headline and Deck – USC News *
New USC Schaeffer Center White Paper Offers Solutions to Ensure Greater Patient Access to Prescription Drugs

Researchers propose three strategies for mitigating negative impacts of the Inflation Reduction Act to ensure greater patient access, increased innovation and lower costs.

Body Copy *
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run.

A new USC Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.

“The IRA lowers drug prices, but at the expense of innovation,” says Dana Goldman, co-director of the USC Schaeffer Center for Health Policy & Economics. “The question is by how much? More transparency around value assessment will improve HHS’ price negotiation process.”

Adverse Effects of the IRA
The IRA made sweeping changes to Medicare’s prescription drug benefit, including requiring the Department of Health & Human Services (HHS) to negotiate “maximum fair prices” with drug manufacturers for brand name drugs with the highest spending that do not have generic or biosimilar competitors. The IRA also penalizes manufacturers who increase list prices faster than inflation and reforms key aspects of the Medicare prescription drug benefit (Part D).

Goldman and colleagues discuss four ways the IRA could negatively impact biomedical innovation and health plan coverage decisions, including a reduction in the discovery of new treatments and new applications for existing treatments, reduced generic competition, and compromises to health plans’ ability to negotiate prices based on value.

“There is an inherent tradeoff here between the patients of today and the patients of tomorrow,” says Erin Trish, co-director of the USC Schaeffer Center. “It is important to recognize and mitigate the potential negative consequences on the latter.”

Regulators Should Focus on Transparency and Value to Mitigate Negative Effects
To mitigate these effects, the white paper offers three recommendations that, when taken together, could help regulators ensure increased innovation, greater patient access and lower costs:

Recommendations for Potential IRA Effects on Drug Pricing
1. Bring transparency and a focus on value to the IRA price-determination process.
To assess value, economists commonly use cost-effectiveness analysis (CEA), but traditional, quality-adjusted life-year-based CEA can discriminate against patients who are disabled, elderly or have complex conditions. Generalized risk-adjusted cost-effectiveness (GRACE) is a new method that takes into account these concerns by aligning estimates with patient preferences. Specifically, GRACE accounts for the fact that people value health gains most when facing very poor quality of life.

“At risk is the ability to put in place a transparent framework that reflects patients’ interests,” says Darius Lakdawalla, director of research at the USC Schaeffer Center. “By using a framework like GRACE, regulators could in a transparent, clear way evaluate the value of new technologies and the benefit they offer to patients.” Without such a framework, it is unclear how patient preferences will be systematically considered, argue the researchers.

2. Incentivize the production of new information about effectiveness.
Many drugs acquire new indications over several years after the drug is launched and real-world data of alternative beneficial uses is gathered, which can help many more patients than originally intended when the drug was discovered. Delaying price negotiation when new, valuable evidence is created would incentivize manufacturers to invest in the clinical trials necessary to gather that evidence.

3. Allow exceptions to the IRA inflation rebates when new evidence is acquired.
Finally, the researchers recommend that HHS implement a more flexible, three-part pricing framework that is tied to real-world data about the value of these drugs, allowing for increased pricing for drugs that work better, and lower prices for those that don’t.

“The U.S. develops more biomedical breakthroughs than any other country,” says Joe Grogan, a nonresident senior fellow at the USC Schaeffer Center. “Regulators need to ensure that the implementation of the IRA does not jeopardize this innovation and the health of future generations.”

The three recommendations aim to balance the IRA’s goals of incentivizing innovation, increasing access and reducing cost.

Funding for this paper was provided by the USC Schaeffer Center. Barry Liden, director of public policy at the Schaeffer Center, Jason Shafrin, senior managing director at the Center for Healthcare Economics and Policy at FTI Consulting and Kyi-Sin Than, director at the Center for Healthcare Economics and Policy at FTI Consulting contributed to the paper.

The post USC Schaeffer Center experts offer solutions to ensure greater patient access to prescription drugs appeared first on USC News.

Publicizing the risks facing pregnant people — especially Black women

It’s fitting that USC celebrated the naming of Allyson Felix Field on Monday, just as Black Maternal Health Week (April 11-17) was about to begin. That’s because Felix — elite athlete, Olympian and entrepreneur — is also a fierce advocate for pregnant people.

“I went through a really difficult time when I decided to start a family. I had been sponsored by Nike for almost a decade and I wasn’t fully supported through my pregnancy — and a lot of other women aren’t as well,” she said Monday in a USC Facebook video. “Our contracts are performance-based; if you have a baby, there’s nothing in place to protect you.”

Felix kept in top shape during her pregnancy by running and swimming. But at 32 weeks, she underwent an emergency cesarean section because of severe preeclampsia– that threatened her life and her baby’s. She shared her story in a widely circulated New York Times op-ed, resulting in policy changes at Nike to support its pregnant athletes.

She’s also become one of the faces of the U.S. Centers for Disease Control and Prevention’s Hear Her campaign to prevent pregnancy-related deaths. The campaign centers on taking the concerns of pregnant women seriously, encouraging health care professionals to listen closely to their patients and be aware of unconscious biases that could shape responses to a potentially fatal problem.

“Medical racism is a significant concern during pregnancy. Many Black mothers report that their symptoms are overlooked or minimized by doctors and nurses, and they may be understandably reluctant to interact with prenatal care providers as a result,” said Darby Saxbe, a professor of psychology at the USC Dornsife College of Letters, Arts and Sciences. “The evidence suggests that pregnancy progresses best when mothers get high-quality social support from their medical care team as well as from their family and community networks.”

Access to basic maternal care major concern for Black women in America

Black women in America are three times more likely to die from pregnancy-related complications than white women, according to federal statistics. This is on top of the fact that women in America are dying at a higher rate from pregnancy-related causes than in any other developed nation. New laws that criminalize abortion care are exacerbating the problem by restricting treatment for miscarriages, ectopic pregnancies and other complications.

“A lack of access to basic women’s health care jeopardizes the health of many pregnant people, particularly people of color. Women of color are two to three times more likely to experience maternal mortality than other groups, which is likely linked to the documented barriers to health care they already face, including lack of access to care, low socioeconomic status, provider bias,” said Nicole Mitchell, an OB-GYN with Keck Medicine of USC.

“Providing women’s health care to these patients, many of whom live in rural communities or states with little to no access to this type of care,” Mitchell continued, “is imperative to reduce the risk of pregnancy complications and maternal mortality, and to protect their personal agency to decide what is best for their health and well-being.”

Emily Smith-Greenaway, an associate professor of sociology and spatial sciences at USC Dornsife, analyzes the influence of mortality conditions on family systems, the impact of child loss on family dynamics and the consequences of community mortality conditions for women’s fertility.

Black Maternal Health Week: Focus provides snapshot of global situation

She said this week’s focus on the state of Black women’s health in the U.S. offers a snapshot of what we see on the global stage.

“Due to structural inequalities, colonial legacies and the pernicious effects of racism, Black women worldwide disproportionately experience poorer reproductive health outcomes — leading them to be more likely to experience maternal morbidity and mortality. And these reproductive inequalities have intergenerational effects,” Smith-Greenaway said. “Black children — from the time of birth — experience higher rates of morbidity and mortality.

“And although we typically think of these inequalities from an individual risk perspective — emphasizing how disparate health outcomes disproportionately burden Black mothers and their children — in my research I seek to emphasize that health disparities not only are reflections of the social and economic inequalities that define our globe but may also have a hand in perpetuating them.”

The post Publicizing the risks facing pregnant people — especially Black women appeared first on USC News.

International study shows link between brain age and stroke outcomes

8277 ebsite *
https://keck.usc.edu/international-study-shows-link-between-brain-age-and-stroke-outcomes/
Story Headline and Deck – USC News *
International study shows link between brain age and stroke outcomes
A USC-led team of researchers find that brain age, a neuroimaging-based assessment of global brain health, may play a role in post-stroke outcomes and could potentially help identify people at risk for poorer outcomes.

Body Copy *
A new study lead by a team of researchers at the Keck School of Medicine of USC shows that younger “brain age,” a neuroimaging-based assessment of global brain health, is associated with better post-stroke outcomes. The findings could lead to better ways to predict post-stroke outcomes and offer insight on new potential treatment targets to improve recovery.

Understanding why some stroke survivors show better recovery than others despite similar damage to the brain has been a critical goal in stroke research, since it could help researchers develop better stroke rehabilitation therapies. During a stroke, blood flow to part of the brain is cut off. Without oxygen, brain cells are damaged and eventually die, resulting in brain damage known as a lesion. Studies have shown that people with similar amounts of lesion damage can experience varying amounts of recovery. Much research in the past two decades has focused on the specific location of brain damage and how the lesion affects connected networks in the brain.

This study, published April 4, 2023 in Neurology(R), takes into consideration global brain health, a new way of analyzing the health of the brain based on its cellular, vascular, and structural integrity. Although global brain health has been widely examined in aging and neurodegenerative disease such as Alzheimer’s disease, it had not previously been studied in relation to stroke rehabilitation outcomes. Led by Sook-Lei Liew, PhD, of the Keck School of Medicine’s Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), the team of researchers focused on a specific measure of global brain health known as brain age, which examines the biology of the nervous system through whole brain structural neuroimaging, hypothesizing that the integrity of residual brain tissue, or what is left after the stroke, may be critical for post-stroke outcomes.

Brain age is a biomarker that predicts chronological age based on neuroimaging of structures such as regional thickness, surface area, and volumes, and is calculated using advanced machine learning algorithms, which have been widely studied at the Stevens INI. A higher brain predicted age difference, calculated as the difference between a person’s predicted brain age minus their chronological age, suggests that the brain appears to be older than the person’s chronological age. An older-appearing brain has been associated with Alzheimer’s disease, major depression, traumatic brain injury, and more.

“Brain age has not been widely explored in stroke. A lot of stroke research has focused on how damage to the brain results in negative health outcomes, but there has been less research on how the integrity of the remaining brain tissue supports recovery. We expected that younger-appearing brains would be buffered from the effects of the lesion damage and therefore have less impacts on behavior,” says Sook-Lei Liew, PhD, lead author of the study and associate professor with joint appointments at the Stevens INI, the Chan Division of Occupational Science and Occupational Therapy, the Division of Biokinesiology and Physical Therapy, and the USC Viterbi School of Engineering.

The research team conducted an observational study using a multi-site data set of 3D brain structural MRIs and clinical measures from ENIGMA Stroke Recovery, a collaborative working group of more than 100 experts worldwide who pool together post-stroke MRI data to create well-powered, diverse samples. The primary mission of the group is to create a worldwide network of stroke neuroimaging centers focused on understanding the mechanisms of stroke recovery.

The new study showed that younger brain age is associated with superior post-stroke outcomes. The researchers note that inclusion of imaging-based assessments of brain age and brain resilience may improve the prediction of post-stroke outcomes and open new possibilities for potential therapeutic targets.

“The health of your overall brain can protect you from the functional consequences of stroke. That is, the healthier your brain is, first, the less likely you are to have a stroke, and second, the less likely you are to have poor outcomes if you do have a stroke. There’s so much research on the aging brain right now, and therapeutics being developed to slow brain aging. This study ties brain aging to stroke outcomes, so any therapeutics developed to slow brain aging might also be helpful to improve outcomes after stroke,” notes Liew.

For this study, the team of experts used high-resolution MRI data from research studies. They plan to progress their brain age assessment work by applying it to routine clinical MRI data to determine if it can be an easily implemented biomarker for stroke rehabilitation outcomes. Researchers at the Stevens INI collaborate on a variety of stroke research, including the Stroke Pre-Clinical Assessment Network (SPAN), which was established to address a significant need in the scientific investigation of stroke treatment. Additionally, Liew and other USC collaborators recently released an expanded, open-source data set of brain scans from stroke patients in hopes of accelerating large-scale stroke recovery research.

For more information, and for a complete list of funding for this research, you can access the paper here.

The post International study shows link between brain age and stroke outcomes appeared first on USC News.

Trojan James Hu went back to school so he could teach leadership to fellow doctors

8240
https://rossier.usc.edu/news-insights/news/usc-rossier-alumnus-james-hu-launches-leadership-training-program-physicians
Story Headline and Deck – USC News *
James Hu back to school so he could teach leadership to fellow physicians
Body Copy *
Top-shelf clinical care and cutting-edge medical research are, for obvious reasons, at the core of Keck Medicine of USC’s mission. But there have been times, according to James Hu MD, EdD ’21, when this laser focus on medical excellence has left its leaders unable to solve problems like physician burnout, lack of engagement and faculty retention.

“Leaders at many academic institutions are chosen because they are experts in their specific fields, not their leadership qualities,” said Hu, a physician and medical director of the Sarcoma Program of USC. “I felt that leaders were coming up with linear solutions to complex problems focused on the individuals and not the work environment.”

Though Hu wanted to help facilitate systemic change within Keck Medicine, he also believed he needed to learn some new, nonmedical skills. In 2018, he decided to pursue a doctorate in organizational change and leadership at the USC Rossier School of Education.

Hu says his time at USC Rossier gave him new insights into the skills that leaders need to employ to lead successful organizations. To put his new knowledge to the test, he is now teaching a leadership training course for program directors and division chiefs at Keck Medicine that is based on research he conducted as an EdD student.

For his dissertation, Hu created a survey that he sent to 1,145 colleagues about physician burnout and leadership behaviors. It helped him understand which leadership behaviors boosted morale and engagement among his colleagues and which fell flat.

Though there are many leadership training courses already available through books, online and in person, the course Hu created, the Keck School of Medicine Leadership Program, is unique because it is homegrown. “This one is grounded in data about our unique opportunities and barriers and being taught by instructors from USC,” said Hu.

In the 11-month program, which launched in the fall, participants attend lectures on subjects including theories of leadership and systems thinking. They do homework and attend in-person sessions to discuss the material as it relates to challenges they are facing. Each student will create an implementation plan to overcome a problem they identify that is unique to their department.

“They will come to learn how to address complex problems and learn when they need to implement new processes because the existing framework is failing,” said Hu. The course is something of a departure, in that teaching colleagues from other USC schools is not the norm, said Maria Ott, the Irving R. and Virginia A. Melbo Chair in Education Administration and a professor of clinical education at USC Rossier. Nevertheless, Ott–one of the instructors in Hu’s course–said the leaders at USC Rossier believe that cross-discipline sharing can be enormously beneficial.

“Leadership development is core to what we do at USC Rossier,” said Ott. “And while people may not think that doctors need leadership training, we believe that every field needs it and can be improved by developing the leadership potential of their team.”

Ott also noted that 27 (more than one-third) of the directors and division chiefs at Keck Medicine signed up for the course, an indication that there is demand for this kind of training and a broad commitment among the leaders at Keck Medicine to improving the organization.

“If we were offering something they didn’t need or didn’t want, they wouldn’t have signed up for it,” said Ott. “It’s a compliment to Dr. Hu because he has a vision about taking a great organization and making it better. I think he has inspired them with his vision of where this organization can go in the future.”

For his part, Hu said he is impressed with the leaders who are taking his course because it is a commitment of time and effort to improve themselves and the organization. “Leadership is incredibly hard,” noted Hu, “but it can be taught, and my hope is that we can grow a cadre of informed and motivated leaders that will affect positive change in the culture of our organization.”

The post Trojan James Hu went back to school so he could teach leadership to fellow doctors appeared first on USC News.

Trojan trailblazer champions diversity at Keck School of Medicine of USC

Looking back on her junior high and high school years in Los Angeles in the 1960s and ’70s, Donna Elliott recalls the education being outdated, with boys and girls often taking different courses based on expectations about their gender.

Title IX logo

“In junior high school, girls did home economics and boys did shop because people thought that girls needed to know how to cook and boys needed to fix things,” said Elliott, a native Angeleno. “And in high school, I did gymnastics and ballet because that’s what the girls did.”

That is not to say that Elliott thought she was destined to take on traditional female roles, such as being a housewife. Her parents, both civil rights activists who fought for more rights and opportunities for people of color in Los Angeles, let her know that she could shoot for the moon.

Her mother was a trailblazer herself, an African American woman who broke through many barriers in both business and health care.

Following her mother’s example

Elliott’s mother was one of three African American women in her class at the Los Angeles County hospital nursing program. She went on to start her own business. While she managed to break gender and racial barriers in both business and health care, it was not without struggle. Elliott said her mother taught her only daughter that success is possible, but it is still harder for women and people of color.

“She often said that you have to work twice as hard to earn half the recognition,” said Elliott.

Fortunately, Elliott never retreated from hard work. She was a stellar student in high school, which earned her admission to USC as an undergraduate where she was, again, a stand-out student. This time, her high marks earned her a spot at the highly rated medical school at USC.

There were just upward of 130 students in her class at what is now the Keck School of Medicine of USC, only 30 of whom were female. Elliott was one of only three young women of color in that class. It wasn’t long before the sexist jabs and, sometimes, outright insults began. Title IX had passed several years before she began medical school, but attitudes don’t always change as quickly as the law.

“We heard it all — that girls should be in the kitchen and not in medical school,” recalled Elliott. Thanks to her mother, Elliott knew exactly what to do in the face of a slight, whether from a male resident or a fellow student: Put your head down and work harder than anyone else.

Diversity matters in medicine

After medical school and completing her residency in pediatrics and a fellowship in pediatric nephrology at the Los Angeles County+USC Medical Center, Elliott joined the faculty of the Keck School of Medicine in 1989. In 2000, she was appointed an assistant dean of student affairs, dean of student affairs in 2007 and vice dean of medical education in 2018.

Over more than two decades of working in student affairs, Elliott has always made admitting and nurturing a diverse student body a core part of her mission. She noted that women now make up more than 50% of the students at the Keck School of Medicine and students from groups underrepresented in medicine make up just over a quarter of the student body, a major change since her days as a medical student at USC.

And while Title IX may have guaranteed young women more spots in graduate education, the law is not the only reason Elliott and the other leaders of the medical school want the doctors of the future to be more diverse. In the years since Title IX passed, numerous studies have proven that diversity among doctors improves the practice of medicine.

“The literature shows that doctors make better decisions when diverse ideas, diverse backgrounds come together to look at a particular problem,” said Elliott.

When it comes to female doctors, noted Elliott, there have been studies that show women spend more time, in general terms, with their patients and communicate better, which can lead to better outcomes for their patients. And while women have made significant strides in medicine since the passage of Title IX, Elliott noted that there is still more work to be done.

“There are undoubtedly many more female doctors, medical school deans and hospital CEOs than 50 years ago,” said Elliott. “It has gotten better, but there is still a way to go.”

The post Trojan trailblazer champions diversity at Keck School of Medicine of USC appeared first on USC News.

$40 million gift to expand research with CHLA that will help generations of patients

USC President Carol L. Folt and Children’s Hospital Los Angeles President and Chief Executive Officer Paul S. Viviano on Monday announced a new, $40 million partnership in biomedical research and innovation initiatives to improve health care. The efforts are based on a gift to USC from the Alfred E. Mann Charities and Alfred E. Mann Foundation for Biomedical Engineering.

“Today’s announcement is testament to the power of connection – between a visionary entrepreneur’s generosity and two recognized leaders in biomedical research and innovation,” Folt said. “This enduring link now allows us to continue our important work, leading to even greater discoveries to improve the lives of children – and the adults they will become.”

Viviano also expressed his appreciation to the foundation and said that the partnership will expand and enhance research opportunities across both institutions.

“We are grateful to the Alfred E. Mann Charities for their tremendous commitment to supporting innovative research and collaboration,” Viviano said. “Our team members look forward to working jointly with USC to make scientific discoveries to improve the lives of children — and the adults they will become.”

USC-CHLA research: Partners for decades

USC and CHLA have been affiliated to advance the health of children in the county and beyond for more than 90 years. CHLA is a regional and national leader in providing clinically superior, specialized and complex pediatric care, reaching 1 in 3 children annually in Los Angeles County alone. This inclusive, compassionate and family-centered clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC.

“As we celebrate this new $40 million partnership with CHLA, we also pay tribute to the late Alfred E. Mann and his visionary donation. Together, we will continue to advance biomedical research and innovation initiatives that aim to improve child health,” said Steven Shapiro, USC senior vice president for health affairs.

The latest gift represents the final distribution of an original donation to USC in 1998 from Mann. Over the course of 25 years, the late inventor and entrepreneur‘s gift, intended for biomedical and biodevice research and development, grew from over $170 million to more than $230 million, presenting USC and the foundation with new opportunities to extend Mann’s legacy.

Folt envisioned the restructuring of the gift to improve health care across all phases of life. In November, she announced the naming of the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences with a $50 million endowment from the foundation. In addition, she announced the naming of the USC Viterbi School of Engineering’s Alfred E. Mann Department of Biomedical Engineering with a $35 million endowment to support education and scholarship.

At a ceremony celebrating the naming of USC Mann School in February, Folt noted Mann’s extensive record of inventions aimed at improving health outcomes.

Throughout his long and distinguished career, Mann founded companies and funded the creation of products that revolutionized the health care field. He also donated more than $174 million to USC toward advancements for human health, including the establishment of the USC Alfred E. Mann Institute, which has been instrumental in creating groundbreaking medical inventions such as the artificial retina. Mann, who died in 2016, was a member of the university’s Board of Trustees and also served on the Board of Overseers of Keck School of Medicine.

USC-CHLA research will enhance innovation across the lifespan

Representatives of the Alfred E. Mann Charities approved redistributing the gift among several initiatives. With this latest distribution, the university and CHLA are collaborating to enhance health care research and innovation across the lifespan — an effort that Mann himself would have supported.

“Al was an outstanding inventor who devoted himself to creative solutions that would improve and extend the lives of millions of people,” said Michael Dreyer, Anoosheh Bostani and Claude Mann of the Alfred E. Mann Charities. “Al would have been so touched to see that his gift is now helping USC and Children’s Hospital Los Angeles to help even the youngest patients to live healthier, longer lives. It is a great way to honor his legacy across generations.”

USC and CHLA will hold an event Monday evening to celebrate the new partnership, with attendees including foundation representatives, faculty, researchers and other supporters.

During the 2022 fiscal year, CHLA treated more than 700,000 patients. As an academic medical center, CHLA is where Keck School of Medicine trains the next generation of pediatricians and where doctors bring a research mindset to treating illnesses.

USC and CHLA have collaborated on innovative cell therapy programs to revolutionize the treatment of a variety of conditions.

Currently, the USC/CHLA Translational Cell Therapy Program consists of 40 principal investigators with more than $56 million in funding from the National Institutes of Health for cell and gene therapy research. Four initiatives have advanced to clinical testing or late pre-clinical development stages; six more are advancing toward clinical development.

In January, USC and CHLA opened a new laboratory to advance early-stage research into lifesaving, commercially viable therapies at the USC Norris Comprehensive Cancer Center. The laboratory is designed to manufacture cell and gene therapies under the Food and Drug Administration’s good manufacturing practice standards.

“The latest gift will undoubtedly strengthen the collaborative work of both institutions,” said Ishwar K. Puri, USC’s senior vice president for research and innovation.

“As recognized leaders in medical research, USC and CHLA bring unique and synergistic strengths,” said Puri. “This gift allows us to nurture new collaborations to produce therapies that improve health and quality of life from childhood through aging.”

The post $40 million gift to expand research with CHLA that will help generations of patients appeared first on USC News.